



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Keefe et al.
SERIAL NUMBER : 10/729,581 EXAMINER : Mark Staples
FILING DATE : December 3, 2003 ART UNIT : 1637
FOR : METHOD FOR *IN VITRO* SELECTION OF 2'-SUBSTITUTED
NUCLEIC ACIDS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents. By the waiver of 37 CFR 1.98(a)(2)(ii) a copy of the U.S. Patent Publication reference A55 is not submitted.

This Supplemental Information Disclosure Statement is being filed after mailing of a First Action on the merits but before mailing of any Final Action or Notice of Allowance under 37 C.F.R. §§1.113 or 1.311, respectively. Accordingly, the fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the


APPLICANTS: **Keefe et al.**
U.S.S.N.: **10/729,581**

information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23239-544.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Customer no.: 69262
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: September 30, 2008

4440849v.1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Keefe et al.
SERIAL NUMBER : 10/729,581 EXAMINER : Mark Staples
FILING DATE : December 3, 2003 ART UNIT : 1637
FOR : METHOD FOR *IN VITRO* SELECTION OF 2'-SUBSTITUTED
NUCLEIC ACIDS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents. By the waiver of 37 CFR 1.98(a)(2)(ii) a copy of the U.S. Patent Publication reference A55 is not submitted.

This Supplemental Information Disclosure Statement is being filed after mailing of a First Action on the merits but before mailing of any Final Action or Notice of Allowance under 37 C.F.R. §§1.113 or 1.311, respectively. Accordingly, the fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the

COPY




APPLICANTS: Keefe et al.
U.S.S.N.: 10/729,581

information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23239-544.

Respectfully submitted,

  
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Customer no.: 69262
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: September 30, 2008

4440849v.1